| Literature DB >> 25477335 |
Pei-Chun Wu1, Jeng-Wei Lu2, Jer-Yen Yang3, I-Hsuan Lin1, Da-Liang Ou4, Yu-Hsiang Lin1, Kuan-Hsien Chou1, Wen-Feng Huang1, Wan-Ping Wang5, Yih-Leh Huang6, Chiun Hsu4, Liang-In Lin7, Yueh-Min Lin8, C-K James Shen9, Tsai-Yu Tzeng10.
Abstract
Aberrant histone methylation is a frequent event during tumor development and progression. KMT1E (also known as SETDB1) is a histone H3K9 methyltransferase that contributes to epigenetic silencing of both oncogenes and tumor suppressor genes in cancer cells. In this report, we demonstrate that KMT1E acts as a metastasis suppressor that is strongly downregulated in highly metastatic lung cancer cells. Restoring KMT1E expression in this setting suppressed filopodia formation, migration, and invasive behavior. Conversely, loss of KMT1E in lung cancer cells with limited metastatic potential promoted migration in vitro and restored metastatic prowess in vivo. Mechanistic investigations indicated that KMT1E cooperates with the TGFβ-regulated complex SMAD2/3 to repress metastasis through ANXA2. Together, our findings defined an essential role for the KMT1E/SMAD2/3 repressor complex in TGFβ-mediated lung cancer metastasis. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25477335 DOI: 10.1158/0008-5472.CAN-13-3572
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701